Table 1.
Summary of the twelve included studies.
| Study | Origin of population | Study design | Disease | N | Stage | NEAT1 assay | Survival analysis | Metastasis analysis | Hazard ratios | Follow-up Months |
|---|---|---|---|---|---|---|---|---|---|---|
| Choudhry16 | UK and Canada | R | BC | 2000 | NA | microarray detection | OS | NA | HR/K-M | 144 |
| Chen17 | China | R | ESCC | 96 | I-II/III-IV | qRT-PCR | OS | LNM/DM | HR/K-M | 80 |
| He18 | China | R | Glioma | 94 | I-II/III-IV | qRT-PCR | OS | NA | HR/K-M | 80 |
| Li19 | China | R | CC | 239 | I-II/III-IV | qRT-PCR | OS, DFS | LNM/DM | HR/K-M | 60 |
| Pan20 | China | R | NSCLC | 57 | I-II/III-IV | qRT-PCR | OS | NA | K-M | 50 |
| Chen21 | China | R | OC | 149 | I-II/III-IV | qRT-PCR | OS | DM | HR/K-M | 70 |
| Fu22 | China | R | GC | 140 | I-II/III-IV | qRT-PCR | OS | LNM/DM | HR/K-M | 96 |
| Lu23 | China | R | NC | 131 | I-II/III-IV | qRT-PCR | OS | NA | K-M | 60 |
| Sun24 | China | R | NSCLC | 96 | 0-I/II-IV | qRT-PCR | OS | LNM | K-M | 40 |
| Chen25 | China | R | BLC | 65 | 0-I/II-IV | qRT-PCR | NA | LNM | NA | NA |
| Hu26 | China | R | NSCLC | 120 | I-II/III-IV | qRT-PCR | NA | NA | NA | NA |
| Li27 | China | R | EEA | 75 | I-II/III-IV | qRT-PCR | NA | LNM | NA | NA |
Study design is described as retrospective (R); BC, Breast Cancer; ESCC, Esophageal Squamous Cell Carcinoma; GC, Gastric Cancer; CC, Colorectal Cancer; NC, Nasopharyngeal Carcinoma; BLC, Bladder Cancer; OC, Ovarian cancer; EEA,endometrial endometrioid adenocarcinoma; DM, distant Metastasis; LNM, Lymph Node Metastasis.